W8MD Diet | COVID-19 portal | Vitamin D | Vaccine | Keto

WikiMD is the world's largest medical encyclopedia with
13,672 pages, 4,140,287 edits & 38,337,121 views.

Free unbiased diet, health and wellness info!


From WikiMD's free health, diet & wellness encyclopedia
Jump to navigation Jump to search
Monoclonal antibody
TypeWhole antibody
Targetbeta amyloid
Clinical data
Other namesBIIB037
ATC code
  • none
CAS Number
  • none
E number{{#property:P628}}
CompTox Dashboard (EPA)
  • {{#property:P3117}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass145.9 kg/mol g·mol−1

Aducanumab is a human monoclonal antibody that was studied for the treatment of Alzheimer's disease (AD).[1] It was developed by Biogen Inc., which licensed the drug candidate from Neurimmune, its discoverer.[2] The antibody targets aggregated forms of β-amyloid found in the brains of people with Alzheimer’s disease, in the hopes of reducing its buildup.[3] Biogen halted development of the drug in March 2019 after preliminary data from two phase III trials suggested it would not meet the primary endpoint.[4][5][6]


Interim results from the second Phase 1 study of the drug were reported in March 2015.[1][7]

A phase 1b study was published in August 2016, based on one year of "monthly intravenous infusions" of aducanumab, with brain scans to measure amyloid plaques.[8] Phase 3 clinical trials were ongoing in September 2016,[8] but were canceled in March 2019 after "an independent group's analysis show[ed] that the trials were unlikely to 'meet their primary endpoint.'"[9]



Aducanumab is part of WikiMD's free ^articles!

^Aducanumab (article) is provided for informational purposes only. No expressed or implied warranties as to the validity of content.
WikiMD is not a substitute for professional advice. By accessing and using WikiMD you agree to the terms of use.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.
W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's physician weight loss program can HELP. Tele medicine available